Pay in 4 interest-free payments of $30.00 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
ES cells) treatment significantly increases the expression of the early neuroectodermal marker Sox1 and the number of cells positive for the neural markers nestin and βIII-tubulin
Tumor growth is inhibited by Ponatinib in a dose-dependent manner compare to vehicle-treated mice
InChi: InChI=1S/C43H53N8O7P/c1-29(2)51(30(3)4)59(56-24-12-23-44)58-36-25-38(50-28-45-39-40(50)47-42(48-41(39)52)46-27-49(5)6)57-37(36)26-55-43(31-13-10-9-11-14-31
sn-Glycerol 3-phosphate is produced by cytosolic glycerol 3-phosphate dehydrogenase pathway through the reduction of dihydroxyacetone phosphate using NADH formed during glycolysis
QS11 binds and inhibits the GTPase activating protein of ARFGAP1
CEP-28122 mesylate salt Catalog No.:M20814-C ES cells) treatment significantly increasesCEP 28122 mesylate salt, a diaminopyrimidine derivative, is a potent, selective, and orally bioavailable ALK inhibitor, with an IC50 value of 1. 9 nM for recombinant ALK kinase activity. CEP 28122 has antitumor activity in experimental models of ALK positive human cancers. CEP 28122 mesylate salt has good pharmacodynamic and pharmacokinetic activity. Product information CAS Number: 2070009 30 0 Molecular Weight: 635. 17 Formula: C29H39ClN6O6S Chemical